GPER1 and neoplasm: Yet they do not resolve whether palbociclib selectively targets proliferation in fulvestrant- resistant, ER-positive breast cancer cells, or whether its actions directly influence GPER-dependent cellular responses associated with tumor cell metastasis and disease progression.